Cash Flow Statement
Growth Metrics

Harvard Bioscience (HBIO) Gross Profit (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Gross Profit for 16 consecutive years, with $14.2 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 1.15% to $14.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.9 million through Dec 2025, down 8.87% year-over-year, with the annual reading at $49.9 million for FY2025, 8.87% down from the prior year.
  • Gross Profit for Q4 2025 was $14.2 million at Harvard Bioscience, up from $12.0 million in the prior quarter.
  • The five-year high for Gross Profit was $19.6 million in Q4 2021, with the low at $11.5 million in Q2 2025.
  • Average Gross Profit over 5 years is $15.0 million, with a median of $15.1 million recorded in 2021.
  • The sharpest move saw Gross Profit dropped 25.36% in 2022, then rose 20.99% in 2023.
  • Over 5 years, Gross Profit stood at $19.6 million in 2021, then dropped by 19.05% to $15.8 million in 2022, then grew by 3.11% to $16.3 million in 2023, then fell by 14.17% to $14.0 million in 2024, then increased by 1.15% to $14.2 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $14.2 million, $12.0 million, and $11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.